Systematic review of pharmacoeconomic studies of pharmacogenomic tests

Pharmacogenomics

Volumn 11, Issue 11, 2010, Pages 1573-1590

  Beaulieu, Mathieu ^a   De Denus, Simon ^a,b   Lachaine, Jean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

cost effectiveness; economic evaluation; evaluation studies; personalized medicine; pharmacogenomics

Indexed keywords

ALEMTUZUMAB; APOLIPOPROTEIN E; ATORVASTATIN; CD20 ANTIGEN; CD33 ANTIGEN; CD52 ANTIGEN; CELECOXIB; CHEMOKINE RECEPTOR CXCR4; CLOPIDOGREL; CODEINE; CYTOCHROME P450 2C9; DENILEUKIN DIFTITOX; DIAZEPAM; ESOMEPRAZOLE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; LENALIDOMIDE; MARAVIROC; NELFINAVIR; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; RITUXIMAB; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TOSITUMOMAB; WARFARIN;

CHROMOSOME 5Q; CHROMOSOME DELETION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; ETHNICITY; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC COUNSELING; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; PHARMACOECONOMICS; PHARMACOGENOMICS; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; GENETIC MARKERS; GENETIC TESTING; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 78649705269     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.145     Document Type: Review

References (57)

1. Allison M: US pharmacies broaden access to pharmacogenetic tests. Nat. Biotechnol. 28(4), 299-300 (2010).
2. Jain KK: Innovative diagnostic technologies and their signifcance for personalized medicine. Mol. Diagn. Ther. 14(3), 141-147 (2010).
3. Guttmacher AE, Mcguire AL, Ponder B, Stefansson K: Personalized genomic information: preparing for the future of genetic medicine. Nat. Rev. Genet. 11(2), 161-165 (2010).
4. Teutsch SM, Bradley LA, Palomaki GE et al.: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP working group. Genet. Med. 11(1), 3-14 (2009).
5. Savage DR: FDA guidance on pharmacogenomics data submission. Nat. Rev. Drug Discov. 2(12), 937-938 (2003).
6. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). In: Health Care Cost, Quality and Outcomes: ISPOR Book of Terms. Marilyn Dix Smith (Ed.). ISPOR Books, NJ, USA (2003).
7. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S: Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 24(4), 355-371 (2006).
8. Weinstein MC, O'Brien B, Hornberger J et al.: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies. Value Health 6(1), 9-17 (2003).
9. Lampe K, Makela M, Garrido MV et al.: The HTA core model: a novel method for producing and reporting health technology assessments. Int. J. Technol. Assess. Health Care 25(Suppl. 2), 9-20 (2009).
10. Payne K, Shabaruddin FH: Cost-effectiveness ana lysis in pharmacogenomics. Pharmacogenomics 11(5), 643-646 (2010).
11. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ: Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 26(7), 569-587 (2008).
12. Jarrett J, Mugford M: Genetic health technology and economic evaluation: a critical review. Appl. Health Econ. Health Policy 5(1), 27-35 (2006).
13. Phillips KA, Van Bebber SL: A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5(8), 1139-1149 (2004).
14. Patrick AR, Avorn J, Choudhry NK: Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fbrillation. Circ. Cardiovasc. Qual. Outcomes 2(5), 429-436 (2009).
15. Leey JA, McCabe S, Koch JA, Miles TP: Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fbrillation. Am. J. Geriatr. Pharmacother. 7(4), 197-203 (2009).
16. Eckman MH, Rosand J, Greenberg SM, Gage BF: Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fbrillation. Ann. Intern. Med. 150(2), 73-83 (2009).
17. You JH, Chan FW, Wong RS, Cheng G: The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision ana lysis. Thromb. Haemost. 92(3), 590-597 (2004).
18. Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG: Economic effciency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 28(11), 1025-1039 (2010).
19. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE: The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22(15), 2025-2033 (2008).
20. Hughes DA, Vilar FJ, Ward CC, Alfrevic A, Park BK, Pirmohamed M: Cost-effectiveness ana lysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14(6), 335-342 (2004).
21. Gold HT, Hall MJ, Blinder V, Schackman BR: Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 115(17), 3858-3867 (2009).
22. Obradovic M, Mrhar A, Kos M: Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 9(5), 539-549 (2008).
23. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ: A cost-effectiveness ana lysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100(10), 2239-2247 (2005).
24. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR: Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of infammatory bowel disease. Aliment. Pharmacol. Ther. 20(6), 593-599 (2004).
25. Priest VL, Begg EJ, Gardiner SJ et al.: Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of infammatory bowel disease. Pharmacoeconomics 24(8), 767-781 (2006).
26. Hagaman JT, Kinder BW, Eckman MH: Thiopurine S-methyltranferase testing in idiopathic pulmonary fbrosis: a pharmacogenetic cost-effectiveness ana lysis. Lung 188(2), 125-132 (2010).
27. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness ana lysis. J. Clin. Oncol. 22(5), 854-863 (2004).
28. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL: The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12(1), 20-27 (2008).
29. Rutjes A, Reitsma J, Coomarasamy A, Khan K, Bossuyt P: Evaluation of diagnostic tests when there is no gold standard: a review of methods. Health Technol. Assess. 11(50), iii, ix-51 (2007).
30. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M: Thiopurine treatment in infammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin. Pharmacokinet. 46(3), 187-208 (2007).
31. Lin JP, O'Donnell CJ, Schwaiger JP et al.: Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114(14), 1476-1481 (2006).
32. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity Am. J. Hum. Genet. 32(5), 651-662 (1980).
33. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
34. Young B, Squires K, Patel P et al.: First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 22(13), 1673-1675 (2008).
35. John T, Liu G, Tsao MS: Overview of molecular testing in non-small-cell lung cancer: mutational ana lysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28(Suppl. 1), S14-S23 (2009).
36. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27(8), 1323-1333 (2009).
37. Hicks DG, Kulkarni S: HER2+ breast cancer: review of biologic releVance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 129(2), 263-273 (2008).
38. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007).
39. Devlin NJ, Hansen P, Kind P, Williams A: Logical inconsistencies in survey respondents' health state valuations - a methodological challenge for estimating social tariffs. Health Econ. 12(7), 529-544 (2003).
40. Yabroff KR, Davis WW, Lamont EB et al.: Patient time costs associated with cancer care. J. Natl Cancer Inst. 99(1), 14-23 (2007).
41. Tappenden P, Jones R, Paisley S, Carroll C: Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol. Assess. 11(12), 1-128, iii-iv (2007).
42. Wilson J, Connock M, Song F et al.: Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol. Assess. 9(25), 1141-142 (2005).
43. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI: Cost-effectiveness ana lysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 15(5), 457-465 (2010).
44. Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH: Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and adjuVant online for early breast cancer. Eur. J. Cancer 46(8), 1382-1391 (2010).
45. Drummond M, Griffn A, Tarricone R: Economic evaluation for devices and drugs - same or different- Value Health 12(4), 402-404 (2009).
46. Hay JW: Using pharmacoeconomics to value pharmacotherapy. Clin. Pharmacol. Ther. 84(2), 197-200 (2008).
47. Schulman KA, Vidal AV, Ackerly DC: Personalized medicine and disruptive innovation: implications for technology assessment. Genet. Med. 11(8), 577-581 (2009).
48. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuVant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
49. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al.: AdjuVant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354(8), 809-820 (2006).
50. Smith I, Procter M, Gelber RD et al.: 2-year follow-up of trastuzumab after adjuVant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555), 29-36 (2007).
51. Special report: pharmacogenomics of cancer-candidate genes. Technol. Eval. Cent. Assess. Program 22(5), 1-3 (2007).
52. KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer. Technol. Eval. Cent. Asses. Program 23 (6), 1-3 (2009).
53. Gene expression profling of breast cancer to select women for adjuVant chemotherapy Technol. Eval. Cent. Assess. Program 22(13), 1-8 (2008).
54. CYP2D 6 pharmacogenomics of tamoxifen treatment. Technol. Eval. Cent. Asses. Program 23(1), 1-4 (2008).
55. Pharmacogenomics-based treatment of Helicobacter pylori infection. Technol. Eval. Cent. Assess. Program 23(2), 1-3 (2008).
56. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in adVanced non-small-cell lung cancer. Technol. Eval. Cent. Assess. Program 22(6), 1-3 (2007).
57. Special report: cardiovascular pharmacogenomics. Technol. Eval. Cent. Asses. Program 22(7), 1-4 (2007).